

Decision number: TPE-D-0000003048-77-05/F

Helsinki, 8 April 2013

**DECISION ON A TESTING PROPOSAL SET OUT IN A REGISTRATION PURSUANT TO ARTICLE 40(3) OF REGULATION (EC) NO 1907/2006****For Dicyclopentylidimethoxysilane, CAS No 126990-35-0 (EC No 404-370-8), registration number: [REDACTED]****Addressee [REDACTED]**

The European Chemicals Agency (ECHA) has taken the following decision in accordance with the procedure set out in Articles 50 and 51 of Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH Regulation).

**I. Procedure**

Pursuant to Article 40(1) of the REACH Regulation, ECHA has examined the following testing proposals submitted as part of the registration dossier in accordance with Articles 10(a)(ix) and 12 (1)(d) thereof for Dicyclopentylidimethoxysilane, CAS No 126990-35-0 (EC No 404-370-8), by [REDACTED] (Registrant:

- Prenatal Developmental Toxicity study (OECD 414) in rats, oral route (gavage).

This decision is based on the registration dossier as submitted with submission number [REDACTED], for the tonnage band of 100 to 1000 tonnes per year.

This decision does not take into account any updates after 02 November 2012, the date upon which ECHA notified its draft decision to the Competent Authorities of the Member States pursuant to Article 51(1) of the REACH Regulation.

This decision does not imply that the information provided by the Registrant in his registration dossier is in compliance with the REACH requirements. The decision does not prevent ECHA to initiate a compliance check on the present dossier at a later stage.

The examination of the testing proposals was initiated upon the date when receipt of the complete registration dossier was confirmed on 27 October 2011. This registration dossier originally contained testing proposals for a sub-chronic toxicity study and a prenatal developmental toxicity study using the analogue substance cyclohexyldimethoxymethylsilane (CAS 17865-32-6).

ECHA held a third party consultation for the testing proposals from 16 December 2011 until 30 January 2012. ECHA received information from third parties (see section III below).

On 23 April 2012 ECHA sent the draft decision to the Registrant and invited him to provide comments within 30 days of the receipt of the draft decision.

On 22 May 2012 ECHA received comments from the Registrant.

On 25 June, 11 and 12 September 2012 the Registrant updated the dossier withdrawing the testing proposal for a sub-chronic toxicity study and amending the proposal for a pre-natal developmental toxicity study proposing this study to be performed on the registered substance instead of an analogue substance. On this basis there was no longer a need to

address in this decision third party comments relating to the withdrawn testing proposal for a sub-chronic toxicity study.

ECHA considered the Registrant's comments received as well as the registration updates received before 2 November 2012 and amended the draft decision.

On 2 November 2012 ECHA notified the Competent Authorities of the Member States of its draft decision and invited them pursuant to Article 51(1) of the REACH Regulation to submit proposals to amend the draft decision within 30 days of the receipt of the notification.

Subsequently, one Competent Authority of a Member State submitted a proposal for amendment to the draft decision.

On 5 December 2012 ECHA notified the Registrant of the proposal for amendment to the draft decision and invited him pursuant to Article 51(5) of the REACH Regulation to provide comments on the proposal for amendment within 30 days of the receipt of the notification.

ECHA reviewed the proposal for amendment received and decided not to amend the draft decision.

The Registrant did not provide any comments on the proposed amendment.

On 17 December 2012 ECHA referred the draft decision to the Member State Committee.

A unanimous agreement of the Member State Committee on the draft decision was reached on 21 January 2013 in a written procedure launched on 11 January 2013. ECHA took the decision pursuant to Article 51(6) of the REACH Regulation.

## II. Testing required

The Registrant shall carry out the following proposed test pursuant to Article 40(3)(a) of the REACH Regulation using the indicated test methods and the registered substance subject to the present decision:

- Pre-natal developmental toxicity study in rats or rabbits, oral route (Annex IX, 8.7.2.; test method: EU B.31/OECD 414).

Pursuant to Articles 40(4) and 22 of the REACH Regulation, the Registrant shall submit to ECHA by **8 April 2014** an update of the registration dossier containing the information required by this decision.

At any time, the Registrant shall take into account that there may be an obligation to make every effort to agree on sharing of information and costs with other Registrants.

## III. Statement of reasons

The decision of ECHA is based on the examination of the testing proposal submitted by the Registrant for the registered substance and scientific information submitted by third parties.

## 1. Prenatal developmental toxicity

### a) Examination of the testing proposal

Pursuant to Article 40(3)(a) of the REACH Regulation ECHA may require the Registrant to carry out the proposed test.

A pre-natal developmental toxicity study for a first species is a standard information requirement as laid down in Annex IX, section 8.7.2. of the REACH Regulation. The information on this endpoint is not available for the registered substance but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

According to the test method EU B.31/OECD 414, the rat is the preferred rodent species, the rabbit the preferred non-rodent species and the test substance is usually administered orally. ECHA considers these default parameters appropriate and testing should be performed by the oral route with the rat or rabbit as a first species to be used.

### b) Consideration of the information received during third party consultation

ECHA received third party information concerning the testing proposal during the third party consultation. For the reasons explained further below the information provided by third parties is not sufficient to fulfil this information requirement.

#### Third party information:

A third party has supported by means of a 'strength and weakness analysis' a read-across strategy from an analogue substance (cyclohexyldimethoxymethylsilane, EC-no.: 402-140-1) to the registered one. ECHA has considered the information provided and concludes that it is not relevant in this case because no experimental data was provided for this analogue substance for prenatal developmental toxicity.

### c) Outcome

Therefore, pursuant to Article 40(3) (a) of the REACH Regulation, the Registrant is required to carry out the following study: Pre-natal developmental toxicity study in rats or rabbits, oral route (test method: EU B.31/OECD 414) using the registered substance.

#### IV. Adequate identification of the composition of the tested material

It is important to ensure that the particular sample of substance tested in the new studies is appropriate to assess the properties of the registered substance, taking into account any variation in the composition of the technical grade of the substance as actually manufactured. If the registration of the substance covers different grades, the sample used for the new studies must be suitable to assess these.

Furthermore, there must be adequate information on substance identity for the sample tested and the grade registered to enable the relevance of the studies to be assessed.

V. General requirements for the generation of information and Good Laboratory Practice

ECHA reminds registrants of the requirements of Article 13(4) of the REACH Regulation that ecotoxicological and toxicological tests and analyses shall be carried out in compliance with the principles of good laboratory practice (GLP).

According to Article 13(3) of the REACH Regulation, tests that are required to generate information on intrinsic properties of substances shall be conducted in accordance with the test methods laid down in a Commission Regulation or in accordance with other international test methods recognised by the Commission or the European Chemicals Agency as being appropriate. Thus, the Registrant shall refer to Commission Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 as adapted to technical progress or to other international test methods recognised as being appropriate and use the applicable test methods to generate the information on the endpoints indicated above.

VI. Information on right to appeal

An appeal may be brought against this decision to the Board of Appeal of ECHA under Article 51(8) of the REACH Regulation. Such appeal shall be lodged within three months of receiving notification of this decision. Further information on the appeal procedure can be found on the ECHA's internet page at [http://echa.europa.eu/appeals/app\\_procedure\\_en.asp](http://echa.europa.eu/appeals/app_procedure_en.asp). The notice of appeal will be deemed to be filed only when the appeal fee has been paid.



Jukka Malm  
Director of Regulatory Affairs